Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
674 results about "Bacteriuria" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Bacteriuria is the presence of bacteria in urine. Bacteriuria accompanied by symptoms is a urinary tract infection while that without is known as asymptomatic bacteriuria. Diagnosis is by urinalysis or urine culture. Escherichia coli is the most common bacterium found. People without symptoms should generally not be tested for the condition. Differential diagnosis include contamination.
Method and apparatus for treatment of congestive heart failure by improving perfusion of the kidney by infusion of a vasodilator
InactiveUS6287608B1Improve the quality of lifeImprove survival rateBiocideInorganic active ingredientsRenin–angiotensin systemVascular dilatation
A method for treating congestive heart failure (CHF) has been developed that restores kidney renal functions by artificial vasodilation of at least one kidney. A vasodilator drug is locally delivered to the kidney via a kidney perfusion catheter. The drug can be mixed with the patient's blood, saline or other suitable solvent and the mixture directly applied to the kidney through the catheter. The restoration of kidney function assists the heart by removing excess fluid, urine and toxin from the patient, and by normalizing the patient's renin-angiotensin system and other neurohormonal substances. The method is applicable to treat chronic and acute CHF.
Owner:GAMBRO LUNDIA AB
Monitoring methods and devices for use therein
InactiveUS6451619B1Reduce unreliabilityLimited usefulnessAnimal reproductionAnalysis using chemical indicatorsBacteriuriaAnalyte
Methods, devices and test kits for monitoring the ovulation cycle, involve testing the body fluid, e.g. urinary, concentration of one or more analytes. Preferably estrone-3-glucuronide and luteinizing hormone are both measured, and a reference concentration for E3G is established at about day 6 of the current cycle. Preferably, disposable testing devices are used, in conjunction with a relatively permanent electronic reader / monitor. The number of "daily" tests required per month can be minimized.
Owner:INVERNESS MEDICAL SWITZERLAND GMBH
Injectable hollow tissue filler
The present invention comprises a plurality of injectable hollow particulate fillers suspended in a biocompatible fluid carrier to significantly improve the clumping resistance and injectability of the composition. The hollow particulate fillers have a lower effective density and are able to suspend in the carrier without precipitation. The loss of skin volume as a result of aging, diseases, weight loss, and injury can lead to uneven skin surface (e.g. wrinkle, etc.). The uneven skin can be repaired by injecting appropriate amount of hollow fillers underneath the skin. Some cases of urinary incontinence occur when the resistance to urine flow has decreased excessively. Continence is restored by injecting the present invention to the urethra tissue to increase resistance to urine outflow. Similarly, the present invention allows for the control of gastric fluid reflux by submucosal injections of the fillers to the esophageal-gastric and gastric-pyloric junction. For patients with vesicoureteral reflux, it can be treated by injection of the present invention into patients' ureteral tissue. This invention can also be used to repair defective or inadequately functioning muscles of the anal sphincter by administering an effective amount of injectable hollow fillers into the defect or anal sinuses.
Owner:CHU JACK FA DE
Kits for diagnosis and monitoring of pathogenic infection by analysis of cell-free pathogenic nucleic acids in urine
The present invention relates to a method for diagnosing and / or monitoring a bacterial or parasitic infection by detection and quantification of the transrenal nucleic acids, derived from bacterial pathogenic agents or from parasites, in urine. The detection method optionally includes the isolation and the purification of the nucleic acids from urine by methods known in the art including pairing with molecular probes that are specific for the pathogenic agents, PCR hybridization, PCR, nested PCR, SSCP, LCR, and SDA. Diagnostic kits based on these detection methods are also claimed.
Owner:INST NAT PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI IRCCS
Methods for detecting early cancer
InactiveUS7090983B1Easy to implementSensitive highPeptide/protein ingredientsMicrobiological testing/measurementBacteriuriaUrine production
MK (midkine) was found to rise in the blood or urine of patients with various types of cancers at early stage. Based on this finding, a method for detecting early cancer, comprising the step of measuring MK in blood or urine was completed.
Owner:MEDICAL THERAPIES
Adam12 as a biomarker for bladder cancer
InactiveUS20090029372A1Improve the level ofLower Level RequirementsMicrobiological testing/measurementMaterial analysisTissue ArraysAffymetrix genechip
The present inventors have shown that the gene and protein expression profiles of ADAM8, ADAM10 and ADAM12 in different grades and stages of bladder cancer.ADAM12 gene expression was evaluated in tumors from 96 patients with bladder cancer using a customized Affymetrix GeneChip. Gene expression in bladder cancer was validated using reverse transcription-polymerase chain reaction (RT-PCR), quantitative PCR, and in situ hybridization. Protein expression was evaluated by immunohistochemical staining on tissue arrays of bladder cancers.The presence and relative amount of ADAM12 in the urine of cancer patients were determined by Western blotting and densitometric measurements, respectively.Particularly ADAM12 mRNA expression was significantly upregulated in bladder cancer, as determined by microarray analysis, and the level of ADAM12 mRNA correlated with disease stage. ADAM12 protein expression correlated with tumor stage and grade. ADAM12 was present in higher levels in the urine from bladder cancer patients than in urine from healthy individuals. Significantly, following removal of tumor by surgery, in most bladder cancer cases examined the level of ADAM12 in the urine decreased and, upon recurrence of tumor, increased.
Owner:PHYSICIANS CHOICE LAB SERVICES +1
Method and Kit for the Early Detection of Impaired Renal Status
InactiveUS20070248989A1Pharmaceutical containersMedical packagingPoint of careExtracorporeal circulation
A method and kit for identifying the presence of an early biomarker of impaired renal status following a renal event in a mammalian subject. The method typically comprises (a) providing a body fluid sample obtained from a mammalian subject following a renal event; and (b) detecting in the provided sample the presence of a protein selected from the group consisting of aprotinin, alpha-1-microglobulin (A1M), alpha-1-acid-glycoprotein (A1AG), microalbumin, and combinations thereof, the presence thereof serving as an early biomarker of a change in renal status. The method can include a kit for point-of-care detection of the early biomarker of impaired renal status. Identification of the presence or absence of the early biomarker typically directs a caregiver's therapeutic decision regarding managing treatment of the subject for impaired renal status The invention also includes a method of assessing the administration of aprotinin during cardiopulmonary bypass surgery and provides for methods where the level of aprotinin in the subject's urine directs a caregiver's therapeutic decision regarding the intra-operative administration of aprotinin.
Owner:NIH
Method for promoting hematopoiesis
InactiveUS6596688B1Reduce plasma virus levelBiocidePeptide/protein ingredientsBacteriuriaChoriogonadotropin Beta
The present invention relates to peptides of one or more portions of the human chorionic gonadotropin beta-chain as well as methods of promoting hematopoiesis, using human chorionic gonadotropin, employing the beta-chain of human chorionic gonadotropin, peptides containing a sequence of one or more portions of the beta-chain of human chorionic gonadotropin and derivatives and analogues thereof. The invention further relates to fractions of sources and or perparations of human chorionic gonadotropin, such as fractions of humna early pregnancy urine, which fractions have pro-hematopoietic activity. The present invention further relates to pharmaceutical compositions for promoting hematopoiesis.
Owner:UNIV OF MARYLAND BIOTECH INST
Cyr61 as a Biomarker for Diagnosis and Prognosis of Cancers of Epithelial Origin
ActiveUS20080286811A1Easy diagnosisRaise the possibilityMicrobiological testing/measurementBiological material analysisBacteriuriaOncology
Urinary Cyr61 protein levels are up regulated in patients that have cancers of epithelial origin, i.e. breast cancer and ovarian cancer. Accordingly, the present invention is directed to methods for prognostic evaluation, and diagnosis of cancers of epithelial origin. Further, the amount of Cyr61 protein detected in a urine sample correlates with disease status such that Cyr61 levels can be used to predict the presence of, as well as the metastatic potential of cancer. Thus, measuring the level of Cyr61 in urine provides a quick, easy, and safe screen that can be used to both diagnose and prognose cancer in a patient.
Owner:CHILDRENS MEDICAL CENT CORP
Adamts-7 as a Biomarker for Cancers of Epithelial Origin
InactiveUS20080268473A1Quick and easy and safeEasy diagnosisBiological material analysisBiological testingBacteriuriaBladder cancer
ADAMTS-7 expression and activity are up regulated in patients that have cancers of epithelial origin. Accordingly, the present invention is directed to methods diagnosis of cancers of epithelial origin (e.g. breast cancer, prostate cancer, bladder cancer, brain cancer and hepatic cancer). In particular, the presence of ADAMTS-7 in a biological sample is indicative of cancer of epithelial origin. Thus, measuring the level of ADAMTS-7 in biological samples (e.g. urine or blood) provides a quick, easy, and safe screen that can be used to diagnose cancer in a patient.
Owner:CHILDRENS MEDICAL CENT CORP
Method and Apparatus for Treatment of Congestive Heart Disease
ActiveUS20070208291A1Increase blood flowImprove kidney functionControl devicesBlood pumpsRenin–angiotensin systemPerfuse kidney
In one aspect, the present invention is directed to an apparatus and method for treating congestive heart failure that restores kidney renal functions by artificial perfusion of at least one kidney. In one aspect, a catheter inserted into the aorta of the patient has an outlet port that supplies the patient's blood obtained from a patient's aorta into an adjoining renal artery of the patient to perfuse the kidney. The catheter comprises a rotor housed inside a portion of the catheter to supply the blood to the kidney at a desired pressure. The restoration of kidney function assists the heart by removing excess fluid, urine and toxin from the patient, and by normalizing the patient's renin-angiotensin system and other neurohormonal substances.
Owner:PATEL VINOD
Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
ActiveUS20100092978A1Inhibit expressionInhibit progressSugar derivativesMicrobiological testing/measurementCancer preventionBacteriuria
Compositions and methods for diagnosing, treating and / or preventing cancers characterized by CDH17 overexpression based on the detection of CDH17 or the use of CDH17 as a target for therapeutic intervention or prophylactic intervention are provided. Methods for diagnosing and / or monitoring liver cancers using the expressing of CDH17 involve detecting and / or quantitating the CDH17 protein or encoding nucleic acids (DNA or RNA) in a biological sample such as urine from the subject. Methods for treating liver cancers using CDH17 as a target and of sensitizing cells with aberrant expression of CDH17 have also been developed. The methods include suppression or knockdown of the expression of CDH17 by administering an effective amount of a CDH17 inhibitor.
Owner:THE UNIVERSITY OF HONG KONG
Method and kit for the early detection of impaired renal status
InactiveUS7662578B2Pharmaceutical containersMedical packagingPoint of careExtracorporeal circulation
Owner:NIH
Predicting urination
InactiveUS20130023786A1Improve forecast accuracyBed wetting preventionDiagnostic recording/measuringBacteriuriaMedicine
Owner:KONINKLIJKE PHILIPS ELECTRONICS NV
A liquid-based cell preservation solution
The invention relates to a pathological examination, in particular to a liquid-based cell preservation solution used in cytopathological examination of human cervical mucus, sputum, urine, pleural fluid, tracheal mucus and the like. It is characterized in that it is prepared from alcohols, sodium phosphate buffer, edetate disodium, sodium chloride 0.08%-0.12%, potassium chloride, formaldehyde, dithiothreitol, calcium acetate, magnesium acetate, etc. As a result, it can not only maintain the stability of the cell structure. It can reduce the agglomeration and precipitation of cell mucus and the loss of cell rupture, and can also make cells easy to stain, improve the clarity of cell preparation, facilitate the smooth progress of pathological examination, and the cost is low, which is conducive to popularization and use.
Owner:XIAOGAN CENT HOSPITAL +1
Bear derived isolate and method
Owner:THE CARLE FOUND
Techniques for evaluating stress urinary incontinence (SUI) using involuntary reflex cough test
ActiveUS20100137737A1Overcome problemsElectromyographyMedical automated diagnosisBacteriuriaUrine leakage
A system and method evaluates a patient for stress urinary incontinence. An involuntary reflex cough event is induced within the patient that activates the nucleus ambiguous and medial motor cell column of the patient and stimulates involuntary cough activated paraspinal muscles in the pelvis of the patient. And elecromyogram (EMG) is obtained from the involuntary cough activated paraspinal muscles and its duration determined. Any urine leakage time that occurs during the involuntary reflex cough event is identified and correlated within a processor together with the urine leakage time and EMG and duration of cough event to determine stress urinary incontinence.
Owner:PNEUMOFLEX SYST
Methods of detecting cancer cells in biological samples
InactiveUS20040197839A1Preparing sample for investigationBiological testingBladder cancerBacteriuria
The invention provides methods of detecting cancerous cells in biological samples using a double staining / dual imaging approach, which can be used to diagnose cancer. More specifically, the present invention provides methods of diagnosing bladder cancer by a simultaneous scanning of cell morphology and FISH signals of cells derived from a urine sample.
Owner:BIOVIEW
Free NGAL as a biomarker for cancer
Uncomplexed neutrophil gelatinase associated lipocalin (NGAL) is present at increased levels in individuals with atypical ductal hyperplasia (ADH), a major risk factor for future breast cancer development; in individuals that have ovarian cancer; and in individuals that have breast cancer, both invasive and noninvasive. Accordingly, the present invention is directed to measuring uncomplexed NGAL levels in urine as a primary screen to determine if an individual is either at risk of developing, or has developed cancer, e.g., cancer of epithelial origin including breast and ovarian cancer.
Owner:CHILDRENS MEDICAL CENT CORP
Method for the in vitro diagnosis of alzheimer's disease using a monoclonal antibody
The invention relates to a method for the in vitro diagnosis of Alzheimer's disease using a monoclonal antibody. Said antibody can bind at least to amino acids 12-16 of the β-amyloid peptide, specifically detecting the neuritic plaques which are characteristic of Alzheimer's disease, without detecting diffuse plaques which are not defining characteristics of the disease. Within the neuritic plaques, the monoclonal antibody can detect a different sub-group in the composition of the different deposited isoforms of the β-amyloid peptide, which is associated with the disease progression stage. In addition, the antibody can bind to isoforms of the β-amyloid peptide in biological fluids such as urine. As a result, the inventive monoclonal antibody, the cell lines that produce said antibody and compositions containing same can be used in the in vitro diagnosis of Alzheimer's disease and in determining the disease progression stage.
Owner:CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Method for detecting alternative biological markers of liver neoplasms in saliva, serum and urine
The invention provides a method for detecting alternative biological markers of liver neoplasms in saliva, serum and urine so as to detect expression information of alternative biological markers of liver neoplasms in a rapid, convenient and accurate manner. The method mainly comprises the following steps of: 1) preparing agglutinin chips corresponding to detection of saliva, serum and urine samples respectively; 2) pretreating stock solutions of saliva, serum and urine samples, removing impurities and purifying proteins, labeling by using a fluorescent reagent and removing redundant fluorescence by using G-25 columns to obtain corresponding samples to be detected; and 3) respectively loading three samples to be detected onto corresponding agglutinin chips to obtain respective glycoprotein sugar chain spectrum in each sample to be detected, and obtain information of the alternative biological markers according to reaction results of any sample to be detected. By the method, the sensibility during detection is high and detection results are accurate; moreover, the method has the advantages of safety, no damage, convenience for sample collection, simplicity in storage and the like.
Owner:NORTHWEST UNIV
Urinary device
ActiveUS20100263113A1Improve hygieneReduce the likelihood of infectionPaper/cardboard wound articlesBathroom accessoriesBacteriuriaDisease
A urinary directional device for improving the directional urination and health of a male user is provided, in which the device comprises a conduit for the passage of urine and having a proximal end adapted for engagement with the penis of the user and a distal end having a distal aperture to enable the passage of urine from the conduit, the device having an interior surface providing one or more of a cleansing, an anti-bacterial or antiseptic or an anti-fungal function whereby the penis of the user can be cleansed by wiping on the interior surface of the device after urination and the device optionally further comprising a health detection indicator capable of indicating abnormalities in urine indicative of disease or health-related conditions.
Owner:AIM STRAIGHT
Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
InactiveUS20090233888A1Lower Level RequirementsElevated level of H2SBiocideOrganic active ingredientsBacteroidesHyperhomocysteinemia
The present invention relates to the treatment of a wide array of diseases and physiologic conditions based on modulating the level of hydrogen sulfide (H2S) in the body by at least partially eradicating small intestinal bacterial overgrowth (SIBO) in the gut. An H2S or lactulose breath test and / or detection of H2S or thiosulfate in the blood or urine may be used as a diagnostic and / or prognostic for assessing a systemic H2S load that exceeds a mammal's natural detoxification capacity. These tests may similarly be used to monitor the effectiveness of a therapeutic intervention for SIBO and / or the diseases or physiologic conditions whose pathology is linked thereto. Because SIBO is related to hyperhomocysteinemia, diseases and physiologic conditions that relate to hyperhomocysteinemia may further be monitored and treated in connection with the methods of the present invention.
Owner:USC STEVENS UNIV OF SOUTHERN CALIFORNIA
Method of administering FimH protein as a vaccine for urinary tract infections
InactiveUS20030138449A1Reduce morbidityInhibit bindingAntibacterial agentsBacterial antigen ingredientsDiseaseBacteroides
The present invention relates to methods of stimulating an immune response in a primate utilizing compositions comprising bacterial adhesin proteins and / or immunogenic fragments thereof. The compositions are useful for the prevention and treatment of bacterial induced diseases involving bacterial adherence to a target cell, such as diseases of the urinary tract. More specifically, the invention relates to the vaccination of primates, preferably humans, with protein complexes, such as a purified FimH polypeptides, a purified FimC-FimH (FimCH) polypeptide complex, or immunogenic fragments thereof, to stimulate protective immunity in the recipient against infection by pathogenic bacteria, including all types of Enterobacteriaceae, preferably E. coli to produce specific immunoglobin molecules in the serum and urine or mucosal secretions of the subject.
Owner:MEDIMMUNE LLC
Lipocalin-2 As A Prognostic and Diagnostic Marker For Heart And Stroke Risks
ActiveUS20090274709A1Easy to adaptPeptide/protein ingredientsMicrobiological testing/measurementCvd riskBlood plasma
Methods and apparatus are disclosed for the measurement of lipocalin-2 in body fluids (including but not limited to blood, serum, plasma, urine, saliva, tear, etc.) by an assay such as an immunoassay or an immunotest for (1) the prediction of risk of future cardiovascular diseases; and (2) the determination of the likelihood that certain individuals will benefit to a greater or lesser extent from the use of certain treatments designed to prevent and / or treat cardiovascular diseases.
Owner:R&C BIOGENIUS +1
Determination method of urine metabolic marker for early diagnosis of diabetic nephropathy.
InactiveCN102901790AAvoid irreversible changesBest time to treatComponent separationTandem mass spectrometryDiabetic nephropathy
The invention discloses a determination method of a urine metabolic marker for early diagnosis of diabetic nephropathy. The method mainly utilizes analysis technique and method such as gas mass spectrometry and mass liquid spectrometry for quantitative determination of endogenous small molecule compounds in urine of patients with diabetes and diabetic nephropathy; and relative concentration difference between endogenous small molecule compounds in a pathological group and a normal group is calculated and compared, so as to be applied to clinical early diagnosis of diabetic nephropathy. Compared with other existing clinical diagnosis indexes, the method has advantages of wide adaptation range, sensitivity, simple sampling and operation, and no harm on the body. The method is more suitable for screening of diabetic nephropathy in early stage with some uncertain physiological and biochemical indexes, so as to avoid missing of the best treatment time due to delayed diagnosis.
Owner:NANJING GENERAL HOSPITAL NANJING MILLITARY COMMAND P L A +1
Methods and kits for diagnosis, prognosis or monitoring of Epstein-Barr virus (EBV)-associated cancer
InactiveUS20080206749A1Lower Level RequirementsEliminate false positive caseMicrobiological testing/measurementFermentationBacteriuriaNon invasive
Disclosed is a non-invasive method for diagnosis, prognosis or monitoring of Epstein-Barr virus (EBV)-associated cancer by detecting and / or quantifying EBV associated nucleic acid fragments in a urine sample from an individual. Kits for diagnosis, prognosis or monitoring of cancer are also disclosed.
Owner:HONG KONG THE CHINESE UNIV OF
Apparatus for extra-labial urine voiding
ActiveUS8337477B2Avoid contactPrevent escapeNon-surgical orthopedic devicesBodily discharge devicesBacteriuriaUrinary excretion
An extra-labia urine voiding apparatus including a container sized and shaped to externally cover a vulval region of a female anatomy. The container has an open side and defines a reservoir that is adapted for receiving urine. The container also includes a substantially planar surface disposed at a top of the container adapted to face and generally surround a periphery of the vulval region. An extra-labia sealing structure is affixed to the planar surface of the top of the container. The sealing structure includes a pressure sensitive adhesive adapted to provide a generally fluid tight primary adhesive seal between the container and external tissue generally surrounding the vulval region. A blocking mechanism connected proximate the top of the container prevents escape of urine from the voiding apparatus and contact of urine with the vulval region of the female anatomy. The voiding apparatus also includes a conduit in fluid communication with the reservoir of the container and adapted for draining urine from the reservoir.
Owner:FEMMED
Method for the early identification and prediction of kidney injury
InactiveUS20090239242A1Convenient treatmentTransferasesDisease diagnosisCreatinine riseElevated blood
A method for the early identification and prediction of elevated blood creatinine levels resulting from a reduction in kidney function in a subject, comprises contacting a urine sample from the subject with a capture molecule for a biomarker specific for the distal region of the renal tubule and which biomarker is released from said region when there is damage to said region indicative and predictive of elevated blood creatinine levels resulting from a reduction in kidney function. The method can be used to detect Acute Kidney Injury (AKI) caused by many conditions or diseases or through the administration of drugs. The method can indicate and / or predict a reduction in kidney function significantly earlier than the current standard creatinine test. Methods for predicting a need for renal replacement therapy (RRT) are also disclosed.
Owner:ARGUTUS INTPROP
Bladder cancer patient urine specific metabolite spectrum, establishing method and application
The invention provides a bladder cancer patient urine specific metabolite spectrum, an establishing method and an application, and especially provides a method for establishing a spectrum of specific metabolites in urine of bladder cancer patients, and a method for screening a related specific biomarker. Through metabonomics, especially metabonomics based on liquid chromatography-mass spectrometry combined technology, the invention establishes a bladder cancer patient urine specific metabolite spectrum. The invention provides a basis for early diagnosis of bladder cancer and bladder cancer diseases with different pathological stages, and also provides a spectrum of specific metabolites in urine of bladder cancer patients and a related specific biomarker. The method provided by the invention has the characteristics of noninvasiveness, convenience, and rapidness, can accurately reflect the difference of metabolite spectra of bladder cancer patients and normal people, and has high specificity.
Owner:BGI GENOMICS CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com